1. Home
  2. RH vs MLYS Comparison

RH vs MLYS Comparison

Compare RH & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo RH

RH

RH

N/A

Current Price

$129.35

Market Cap

2.2B

ML Signal

N/A

Logo Mineralys Therapeutics Inc.

MLYS

Mineralys Therapeutics Inc.

N/A

Current Price

$15.41

Market Cap

1.9B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
RH
MLYS
Founded
1979
2019
Country
United States
United States
Employees
N/A
N/A
Industry
Other Specialty Stores
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.2B
1.9B
IPO Year
2011
2023

Fundamental Metrics

Financial Performance
Metric
RH
MLYS
Price
$129.35
$15.41
Analyst Decision
Hold
Strong Buy
Analyst Count
20
11
Target Price
★ $163.76
$43.56
AVG Volume (30 Days)
711.4K
★ 1.9M
Earning Date
12-10-2026
11-04-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 74.31
37.43
EPS
★ 2.36
N/A
Revenue
★ $1,193,046,000.00
N/A
Revenue This Year
$5.68
N/A
Revenue Next Year
$9.26
N/A
P/E Ratio
$54.88
★ N/A
Revenue Growth
★ 24.52
N/A
52 Week Low
$106.30
$14.78
52 Week High
$239.40
$45.00

Technical Indicators

Market Signals
Indicator
RH
MLYS
Relative Strength Index (RSI) 46.44 32.09
Support Level $123.55 N/A
Resistance Level $137.90 $31.19
Average True Range (ATR) 7.60 1.53
MACD -1.24 -0.05
Stochastic Oscillator 14.50 7.66

Price Performance

Historical Comparison
RH
MLYS

About RH RH

RH is a luxury furniture and lifestyle retailer primarily operating in the $136 billion domestic furniture and home furnishing industry. The firm offers merchandise across many categories, including furniture, lighting, textiles, bath, decor, and has a growing presence in hospitality with 27 restaurant locations, including RH Guesthouse. RH innovates, curates, and integrates products, categories, services, and businesses across design subcategories (RH Estates and Waterworks, for example), and has recently broadened its addressable market via expansion abroad (currently, less than 10% of sales) and its World of RH digital platform (highlighting offerings outside of home furnishings).

About MLYS Mineralys Therapeutics Inc.

Mineralys Therapeutics Inc is a biopharmaceutical company focused on developing medicines to target diseases driven by dysregulated aldosterone. The Company's product candidate, lorundrostat, is a proprietary, orally administered, aldosterone synthase inhibitor that the Company is developing for the treatment of cardiorenal conditions affected by dysregulated aldosterone, including hypertension and related comorbidities, such as chronic kidney disease and obstructive sleep apnea. Its product candidate, lorundrostat, is a proprietary, orally administered, selective ASI that is designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for producing the hormone.

Share on Social Networks: